Table 4.

Side effects of ¹⁷⁷Lu-PSMA-617 treatment

Patient	Accumulated activity (GBq)		Number of cycles		Therapy-related side effects
Hematoxicity (Grade)	Hepatotoxicity (Grade)		Nephrotoxicity (Grade)		Xerostomia
1	17.7	3	I → I	I → I	0	0
2	19.3	4	0	I → I	I → I	0
3	18.6	4	I → I	I → I	0	0
4	16.3	3	0	0	0	Transient
5	17.9	4	I → I	I → I	0	Permanent
6	18.1	4	0	I → I	0	0
7	18.8	3	0	I → I	0	0
8	12.7	2	I → I	I → I	I → II	Transient
9	18.6	3	II → II	II → II	0	0
10	24.32 + 11.84	4 + 2	0	I → I	0	0
11	25.61 + 12.52	4 + 2	0	0	0	0
12	12.79	2	I → I	0	II → III	Transient
13	25.32	4	I → I	I → II	0	0
14	24.9	4	I → I	0	II → II	Transient
15	18.29	3	I → I	0	I → I	0
16	23.34	4	0	II → II	0	0
17	24.93	4	0	0	I → I	0
18	18.1	3	I → I	0	0	Transient
19	24.4	4	I → I	0	I → I	Permanent
20	24.8 + 12.33	4 + 2	0	0	0	0
21	10.76	2	I → I	0	II → II	0
22	23.84	4	0	0	I → I	0
23	24.61	4	0 →0	0	0	0
24	25.27	4	I →I	I →II	0	0
25	24.38	4	I→I	0→0	0→I	0
26	25.34	4	I→I	0→0	0→I	0
27	19	3	0→I	0→II	0→0	0
28	21.95 + 3.05	4 + 1	0→I	II→II	II→III	0
29	16.04	3	I→I	0→I	I→III	0
30	25.54	4	I → I	0 → 0	0 → 0	0
31	23.74	4	I → I	0 → 0	0 → 0	0
32	21.49	4	I → I	0 → I	I → I	Transient